MyCan Technologies K.K. (Head office: Kyoto, Japan; Representative Director: Kazuo Miyazaki) has announced that Realtech Fund No. 3 Investment Limited Partnership (General Partner: Realtech Japan, LLC; Minato-ku, Tokyo; Representative Operating Officer: Akihiko Nagata), Globis Alumni Growth Investment No. 1 Fund (Operating Partner: Globis, Inc, GLOBIS Alumni Growth Investment No. 1 Fund (managing partner: GLOBIS Corporation, Chiyoda-ku, Tokyo; Representative Director: Yoshito Hori), Kyoto City Startup Support No. 2 Investment Limited Partnership and Kobe Shinkin Step Up Investment Limited Partnership (unlimited liability partner; Future Venture Capital Co: Future Venture Capital Corporation (Kyoto-shi, Kyoto; President: Naoto Matsumoto), and 360ip Japan Fund No. 1 Investment Limited Partnership (unlimited liability partner: 360ip Japan K.K.; Bunkyo-ku, Tokyo; Representative Director: Asaishi Mori). (unlimited liability partner: 360ip Japan K.K., Bunkyo-ku, Tokyo; Representative Director: Asashi Mori).
With this capital increase, MyCan Technologies will accelerate product development of prediction kits for the severity of infectious diseases using the iPS cell-derived immortalized myeloid lineage cells (iMylc cells) products it is offering. The development of a new type of kit for predicting the severity of viral infections by measuring the quality of antibodies in the body, with a particular focus on viral infections such as dengue hemorrhagic fever and new coronavirus infections. Through the development and commercialization of the kit, MyCan Technologies aims to realize its wish of "a society where people can live without fear of infectious diseases.
About Mylc Cells
Mycan Technologies has the technology to produce and supply immortalized myeloid lineage cells (Myelc cells: one of immune cells, including monocytes and dendritic cells) derived from human iPS cells and other cells using regenerative medicine technology. Since they can produce large quantities, a stable and continuous supply is possible. Therefore, they are used as research cells for infectious diseases such as dengue virus and new coronavirus, as well as for research on immunity.
The use of Mylc cells to predict the severity of viral infections
Mylc cells are capable of reproducing human immune responses in a state close to that of a living organism. When viruses or microorganisms are present, Mylc cells become infected and the microorganisms proliferate, or conversely, Mylc cells produce inflammatory cytokines (IL-6, etc.) for defense, which are reactions that occur in the body. It has been found that the reactivity of infection and defense in such immune reactions differs greatly when there is a sample (antibody to be tested, e.g., blood or serum). Therefore, based on this reaction, we aim to develop and commercialize the world's first kit for predicting the severity of viral infections using regenerative medicine technology.
About MyCan Technologies
Since its establishment in 2016, the company has supported the development of therapeutic drugs and vaccines by providing blood cells for research using regenerative medicine technology, and hopes to develop and provide products even closer to patients than before. By using MyCan Technologies' proprietary technology to develop a test drug business that predicts the severity of illness, the company expects to make an even greater contribution to the realization of a "society where people can live without fear of infectious diseases.









